Patents by Inventor Andrzej Dekundy

Andrzej Dekundy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ELTOPRAZINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA
    Publication number: 20110288105
    Abstract: The present invention relates to the treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition may arise as a consequence of long-term treatment with L-DOPA therapy in Parkinson's patients, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 4, 2009
    Publication date: November 24, 2011
    Applicant: Merz Pharma GmbH & Co. KGaA
    Inventors: Barbara Valastro, Andrzej Dekundy, Frank Tennigkeit, Hermann Russ, Lutz Franke
  • Pyrazolopyrimidines for treating CNS disorders
    Publication number: 20110212956
    Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
    Type: Application
    Filed: May 3, 2011
    Publication date: September 1, 2011
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaitas, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators
    Patent number: 7985753
    Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: July 26, 2011
    Assignee: MERZ PHARMA GmbH & Co. KGaA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators
    Patent number: 7947689
    Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: May 24, 2011
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine
    Publication number: 20080039458
    Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 14, 2008
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Pyrazolopyrimidines, a process for their preparation and their use as medicine
    Publication number: 20080039476
    Abstract: The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2 and Y3 independently are e.g. CR10, NH, S or O, whereby at least one of Y1, Y2 and Y3 represents CR10; R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 represent e.g. hydrogen or C1-C6-alkyl, and R10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 14, 2008
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Graham Raphael Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss
  • Pyrazolopyrimidines, a process for their preparation and their use as medicine
    Publication number: 20080032998
    Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein R1 represents chloro or bromo; R2, R3, R4, R5, R6 and R7 independently represent e.g. hydrogen or C1-6-alkyl; R8 represents a radical R9 or a radical R10, whereby one of the two radicals R8 represents R9 and the other radical R8 represents Ret; R9 represents e.g. a phenyl or thiophene group, and R10 represents e.g. hydrogen or methyl; are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 7, 2008
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Wojciech Danysz, Andrzej Dekundy, Mirko Hechenberger, Markus Henrich, Claudia Jatzke, Jens Nagel, Christopher Parsons, Tanja Weil, Juris Fotins, Aleksandrs Gutcaits, Ivars Kalvinsh, Ronalds Zemribo, Valerjans Kauss